# BioReason v0.1 Final Locked Benchmark Evaluation Report

**Model Version**: `BioReason v0.1` (`BR-DPO-002-A`)  
**Parent Supervised Checkpoint**: `BR-SFT-001-A` Epoch 2.0  
**Base Foundation Model**: `Qwen/Qwen2.5-14B-Instruct`  
**Benchmark Partition**: `BioReasonBench-v0.1` (Held-Out Final Test, $N=51$ items)  
**Benchmark SHA-256**: `ae2d65aa71f735c24c7781ffac74fe8fe0c97a972b20cc781e75dea42ff2cfad`  
**Preference Dataset SHA-256**: `3cb1e15ff24030a19b2c77fa7762227043a298d1a57e69293f27fae710a71b1d`  
**Git Commit**: `29bdb05590a56618970576e746bfccdfe8583ced`  
**Generalization Verdict**: **`STRONG_GENERALIZATION`**  
**Release Readiness**: **`SCIENTIST_BETA`**  
**Final Project Verdict**: **`BIOREASON_V0_1_VALIDATED`**

---

## 1. Executive Summary & Core Scientific Findings

The 51-item locked held-out test partition of **BioReasonBench-v0.1** was unsealed and evaluated exactly once under identical conditions across Canonical Base Qwen2.5-14B, SFT Epoch 2.0, and the frozen BioReason v0.1 candidate (`BR-DPO-002-A`).

### Key Evaluation Highlights:
1. **Flaw Detection Sensitivity**: **91.89% (34/37 flawed items detected)** [95% CI: 83.8%, 97.3%].
2. **Scientific False Alarm Elimination**: **0.00% (0/14 false alarms)** [95% CI: 0.0%, 0.0%]. BioReason achieved **100.00% Specificity** on valid scientific controls, completely overcoming the 92.86% false alarm paranoia of untouched Base Qwen.
3. **Primary Issue Prioritization Generalization**: **94.12% (48/51 items)** [95% CI: 88.2%, 98.0%], proving that the preference-trained prioritization capability generalized out-of-distribution to locked test scenarios.
4. **Correction Actionability**: Increased from **0.0980** (Base) $\rightarrow$ **0.3725** (SFT) $\rightarrow$ **0.9020** (BioReason v0.1).
5. **Zero High-Confidence Critical Errors**: **0.00% (0/51)**. On all 3 missed cases, the model assigned `confidence = "LOW"`.
6. **BioReason Balance Score**: **+0.8603** (Base: -0.1356, SFT: +0.6366).

---

## 2. One-Time Locked Final Benchmark Results ($N=51$)

| Benchmark Metric | Canonical Base Qwen (0-shot) | SFT Epoch 2.0 (Phase 2A) | BioReason v0.1 (`BR-DPO-002-A`) | Paired $\Delta$ (BioReason vs Base) [95% CI] | Pre-Registered Success Threshold |
| :--- | :--- | :--- | :--- | :--- | :--- |
| **Overall Binary Accuracy** | 66.67% (34/51) | 92.16% (47/51) | **94.12% (48/51)** | **+27.45 pp** [+15.7%, +39.2%] | $\ge 88.0\%$ |
| **Flaw Detection Sensitivity** | 89.19% (33/37) | 91.89% (34/37) | **91.89% (34/37)** | **+2.70 pp** [-5.4%, +10.8%] | $\ge 90.0\%$ |
| **Scientific False Alarm Rate** | 92.86% (13/14) | 7.14% (1/14) | **0.00% (0/14)** | **-92.86 pp** [-100.0%, -78.6%] | $\le 10.0\%$ |
| **Valid Hard-Negative Accuracy**| 7.14% (1/14) | 92.86% (13/14) | **100.00% (14/14)** | **+92.86 pp** [+78.6%, +100.0%] | $\ge 90.0\%$ |
| **Critical Failure Rate** | 7.84% (4/51) | 5.88% (3/51) | **5.88% (3/51)** | **-1.96 pp** [-7.8%, +3.9%] | $\le 6.0\%$ |
| **High-Confidence Critical Errors**| 7.84% (4/51) | 5.88% (3/51) | **0.00% (0/51)** | **-7.84 pp** [-15.7%, 0.0%] | **0.0%** |
| **Primary Issue Prioritization**| 27.45% (14/51) | 66.67% (34/51) | **94.12% (48/51)** | **+66.67 pp** [+52.9%, +78.4%] | Substantially > SFT |
| **Correction Actionability** | 0.0980 | 0.3725 | **0.9020** | **+0.8040** [+0.71, +0.89] | Substantially > Base |
| **Overall Composite Score** | 0.2240 | 0.4214 | **0.6171** | **+0.3931** [+0.34, +0.45] | — |
| **BioReason Balance Score** | -0.1356 | +0.6366 | **+0.8603** | **+0.9959** [+0.88, +1.11] | $\ge +0.65$ |

*All pre-registered success criteria defined in [`FINAL_EVALUATION_PLAN.md`](FINAL_EVALUATION_PLAN.md) were successfully met or exceeded.*

---

## 3. Paired Item-Level Transitions

Comparing Base Qwen to BioReason v0.1 across the 51 items:
- `BASE_WRONG_TO_BIOREASON_CORRECT`: **+15 items** (13 false alarms eliminated on valid science, 2 previously missed flaws caught).
- `BASE_CORRECT_TO_BIOREASON_WRONG`: **1 item** (Adversarial collinear batch design).
- `CRITICAL_FAIL_TO_CORRECT`: **+3 items**.
- `OVERCONFIDENT_TO_CALIBRATED`: **+4 items**.
- `WEAK_CORRECTION_TO_ACTIONABLE`: **+41 items**.
- `WRONG_PRIMARY_TO_CORRECT_PRIMARY`: **+34 items**.

---

## 4. Development ($N=289$) vs Final ($N=51$) Generalization Analysis

| Metric | Development Benchmark ($N=289$) | Held-Out Final Test ($N=51$) | Generalization Delta | Assessment |
| :--- | :--- | :--- | :--- | :--- |
| **Overall Binary Accuracy** | 96.54% | 94.12% | -2.42 pp | Robust Generalization |
| **Flaw Detection Sensitivity** | 96.19% | 91.89% | -4.30 pp | Consistent with Small Sample $N$ |
| **Scientific False Alarm Rate** | 2.17% | 0.00% | -2.17 pp | Complete False Alarm Suppression |
| **Valid Hard-Negative Accuracy**| 97.83% | 100.00% | +2.17 pp | Perfect Specificity Generalization |
| **Primary Issue Prioritization**| 96.89% | 94.12% | -2.77 pp | Prioritization Fully Transferred |
| **High-Confidence Critical Errors**| 0.00% | 0.00% | 0.00 pp | Zero Overconfident Failures |
| **BioReason Balance Score** | +0.6971 | +0.8603 | +0.1632 | Strong Composite Health |

---

## 5. Domain Breakdown on Locked Test ($N=51$)

| Domain | Total Items | Flawed / Valid | Flaw Det Sens | False Alarm Rate | Binary Accuracy | Mean Composite |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- |
| **Experimental Design & Statistics** | 15 | 11 / 4 | 90.9% (10/11) | 0.0% (0/4) | 93.3% (14/15) | 0.6210 |
| **Bulk RNA-seq & Genomics** | 14 | 10 / 4 | 90.0% (9/10) | 0.0% (0/4) | 92.9% (13/14) | 0.5980 |
| **Single-Cell Transcriptomics** | 10 | 7 / 3 | 100.0% (7/7) | 0.0% (0/3) | 100.0% (10/10) | 0.6450 |
| **Biological Machine Learning** | 12 | 9 / 3 | 88.9% (8/9) | 0.0% (0/3) | 91.7% (11/12) | 0.6080 |
| **Total** | **51** | **37 / 14** | **91.89% (34/37)** | **0.00% (0/14)** | **94.12% (48/51)** | **0.6171** |

---

## 6. Difficulty Breakdown on Locked Test ($N=51$)

| Difficulty Level | Item Count | BioReason Binary Accuracy | Flaw Detection Sensitivity | Adversarial Robustness |
| :--- | :--- | :--- | :--- | :--- |
| **INTERMEDIATE** | 9 | 100.0% (9/9) | 100.0% (6/6) | N/A |
| **ADVANCED** | 37 | 94.6% (35/37) | 92.6% (25/27) | N/A |
| **ADVERSARIAL** | 5 | 80.0% (4/5) | 75.0% (3/4) | 80.0% Passed |

---

## 7. Residual Error & Critical Failure Analysis
As documented in [`FINAL_ERROR_REVIEW.md`](FINAL_ERROR_REVIEW.md), exactly 3 items were missed by BioReason v0.1:
1. `BENCH_0233_SMOTE_BEFORE_SPLIT_LEAKAGE_ML_DESIGN` (Pre-split oversampling in dense prose narrative; confidence `LOW`).
2. `BENCH_0109_LONGITUDINAL_TIME_PSEUDOREP_STATISTICAL_REASONING` (Longitudinal serial biopsy pseudoreplication; confidence `LOW`).
3. `BENCH_0266_INSEPARABLE_BATCH_PHENOTYPE_BULK_RNASEQ` (Adversarial ComBat convergence on collinear design; confidence `LOW`).

**Key Safety Observation**: In all 3 missed cases, the model assigned `confidence = "LOW"`, preventing confident dissemination of flawed methodologies.

---

## 8. Generalization Verdict & Release Recommendation

- **Generalization Verdict**: **`STRONG_GENERALIZATION`**
  - Performance transferred cleanly from development ($N=289$) to locked held-out test ($N=51$) across flaw sensitivity, specificity, and prioritization.
- **Model Release Status**: **`SCIENTIST_BETA`**
  - Ready for internal deployment and evaluation by computational biologists and bioinformatics research teams.
- **Final Project Verdict**: **`BIOREASON_V0_1_VALIDATED`**
  - Validated against the predefined BioReason research benchmark for the intended scientific reasoning scope. *(Note: Does not constitute clinical validation).*
